This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.–11. (Canceled)

12. (Previously Presented) A compound of formula II



II

wherein radical R is:

$-(CH_2)_n-CH_2-R^1$, $-(CH_2)_n-CH_2-OR^1$, $-(CH_2)_n-CH_2-OCOR^1$, $-(CH_2)_n-CH_2-SR^1$, $-(CH_2)_n-CH_2-NR^1R^2$, $-(CH_2)_n-CHO$, $-(CH_2)_n-CN$, in which n can assume the values of 0-5, and radicals R^1 and R^2, independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

13. **(Currently Amended)** ~~Process~~ A process for the production of 5β-substituted androst-9(11)-enes of general formula II according to claim 12 by reaction of a compound of general formula I:



I

in which X = a halogen radical or a radiohalogen radical to form 17β-silyl ether of formula Ia



O-silyl group

Ia

in which X = halogen, selected from Br or I and further reaction with mercaptoacetic acid methyl ester for the formation of 17β-silylated-3-oxo-2'H,5'H-thieno[3',4':5,10]-5β-estr-9(11)-ene-2'ξ-carboxylic acid methyl ester, which then is reacted ~~according to processes that are known in the art analogously to Diagram 2~~ to form ~~the~~ a target ~~compounds~~ compound of Formula II:



II

wherein radical R is:

$-(CH_2)_n-CH_2-R^1$, $-(CH_2)_n-CH_2-OR^1$, $-(CH_2)_n-CH_2-OCOR^1$, $-(CH_2)_n-CH_2-SR^1$, $-(CH_2)_n-CH_2-NR^1R^2$, $-(CH_2)_n-CHO$, $-(CH_2)_n-CN$, in which n can assume the values of 0-5, and radicals R^1 and R^2, independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

14. (Currently Amended) ~~Use of the compounds of general formula II according to claim 12 for treatment of~~ A method of treating an androgen-dependent ~~diseases~~ disease, comprising administering an effective amount of a compound according to claim 12 to a patient in need thereof.

15.–23. (Canceled)

24. (Previously Presented) A composition comprising a compound according to claim 12 and a pharmaceutically acceptable carrier.

25. (Previously Presented) A method of treating an androgen-dependent disease comprising administrating an effective amount of a compound according to claim 12.

26. (Previously Presented) A compound according to claim 12, wherein R is an ethyl group.

27. (New) A compound according to claim 12, wherein R is 2-(2-pyrimidylsulfanyl)-ethyl, 2-(heptylsulfanyl)-ethyl, 2-[(1-methyl-1H-imidazole-2-yl)sulfanyl]ethyl, 2-(benzothiazole-2-yl)-sulfanyl, or [2-(thiene-2-yl)-sulfanyl]ethyl.